Innate Pharma (IPHA) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to -$67.9 million.
- Innate Pharma's Enterprise Value rose 3126.64% to -$67.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$67.9 million, marking a year-over-year increase of 3126.64%. This contributed to the annual value of -$87.4 million for FY2024, which is 1258.94% up from last year.
- Per Innate Pharma's latest filing, its Enterprise Value stood at -$67.9 million for Q2 2025, which was up 3126.64% from -$86.3 million recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Enterprise Value ranged from a high of -$67.9 million in Q2 2025 and a low of -$143.7 million during Q2 2021
- Moreover, its 5-year median value for Enterprise Value was -$99.5 million (2023), whereas its average is -$107.3 million.
- Per our database at Business Quant, Innate Pharma's Enterprise Value skyrocketed by 9990.27% in 2021 and then tumbled by 213.22% in 2024.
- Quarter analysis of 5 years shows Innate Pharma's Enterprise Value stood at -$137.1 million in 2021, then rose by 24.47% to -$103.5 million in 2022, then rose by 3.92% to -$99.5 million in 2023, then grew by 13.24% to -$86.3 million in 2024, then rose by 21.27% to -$67.9 million in 2025.
- Its Enterprise Value was -$67.9 million in Q2 2025, compared to -$86.3 million in Q4 2024 and -$98.9 million in Q2 2024.